Wolfgang J. Rettig

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +11

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

Frank Hilberg, Gerald J. Roth, Martin Krššák et al. · Cancer Research · 2008 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo

Martin Steegmaier, Matthias Hoffmann, Anke Baum et al. · Current Biology · 2007 · 849 citations · Full text

Medicine, Oncology, Pharmacology +14

Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

Pilar Garin‐Chesa, Lloyd J. Old, Wolfgang J. Rettig · Proceedings of the National Academy of Sciences · 1990 · 738 citations

Veterinary Medicine, Oncology, Pathology +17

The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1

Péter Lénárt, Mark Petronczki, Martin Steegmaier et al. · Current Biology · 2007 · 677 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17